top of page

Jennifer Collins

PharmD, BCOP


Inpatient Cell Therapy, Outpatient BMT Clinic


PharmD: Belmont University

Residency Training

PGY1: University of Chicago Medicine
PGY2 Oncology: University of Chicago Medicine

Jennifer Collins

Practice Interests

Cellular therapy, immunocompromised ID

Professional Affiliation

  • Hematology/Oncology Pharmacists Association (HOPA)

  • American Society for Transplantation and Cellular Therapy (ASTCT) - Research SIG Committee Member

  • Advanced Topics for Oncology Pharmacy Professionals (ATOPP) - Planning Committee

Recent Publications

  • Collins J, Serbas L, Parsad S. Considerations for Initiation of Lu-Dotatate therapy at a large academic medical center. Oncolytics Today. 2021. 35-39.

  • Riedell PA, Wu Meng, Collins JM, et al. Bloodless chimeric antigenreceptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk & Lymphoma. 2020.

  • Major A, Collins JM, Craney C, et al. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: A case report and review of the literature. Leuk & Lymphoma. 2020.

  • Collins JM, Gawedzki P. Impact of the Implementation of a Pharmacist-Driven Immunosuppression Drug Monitoring Protocol for Hematopoietic Stem Cell Transplant Recipients Biology of Blood and Marrow Transplantation. J Oncol Pharm Practice. 2020. 1-7.

  • Collins JM, Dennis EE, Green MW, and Greene EM. Patient self-prescription and antimicrobial stewardship: considerations for primary care. J APhA. 2020. 1-4.

  • Collins JM, et al. The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. J Oncol Pharm Practice. 2019. DOI 10.1177/1078155219833440

  • Collins JM, Flemin GF, and Christ TN. Comparison of the incidence of febrile neutropenia in obese and and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Practice. 2018. DOI 10.1177/1078155218776471

  • Collins JM, Duvall AS, Dworkin E, Stock W, and Castiel M. A systematic approach to the management of menses prophylaxis and suppression in pre-menopausal hematologic cancer patients. Pending.

Academic and/or National Presentations

  • Immune Effector Cell Therapy Part I: Basics and Updates. 2022 ASTCT Fundamentals of HCT Training Course (Virtual)

  • Best Practices: CAR-T Therapy Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR February 2022? (Salt Lake City, UT)

  • Effect of Posaconazole on Tacrolimus Levels in Allogeneic Stem Cell Transplant Patients - May 2018 at the HOPA Annual Conference (Denver, CO)

  • QTc Monitoring in Patients on Prophylactic Azithromycin and Antidepressants - December 2017 at the ASHP Midyear Meeting (Orlando, FL)

  • Incidence of Febrile Neutropenia in Obese Breast Cancer Patients Receiving Pegfilgrastim - December 2016 at the ASHP Midyear Meeting (Las Vegas, NV) 

  • Antimicrobial Stewardship: Considerations for Primary Care - December 2015 at the ASHP Midyear Meeting (New Orleans, LA)

Current Research

  • Impact of Neutrophil-Mediated Initiation of Anti-Infective Prophylaxis in Cell Therapy Patients

  • The Influence of Gut Decontamination Prophylactic Antibiotics on Allogeneic Hematopoietic Stem Cell Transplant Outcomes In Collaboration with Kaitlin Kelly, PharmD

  • Association of Tacrolimus Levels with GVHD Incidence and Toxicity In Collaboration with Mylove Mortel, MSPH, RN, OCN and Zaheera Shabbir, PharmD

  • The Utility of Proton Pump Inhibitor Prophylaxis in Hematologic Cancer Patients in Collaboration with Ben Bowar, PharmD

bottom of page